hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06286085 id: 337788 briefTitle: A Comparison of Diagnostic Testing Modalities in the Assessment of Asthma acronym: MODELS overallStatus: RECRUITING date: 2024-02-27 date: 2024-04-24 date: 2024-07-24 date: 2024-02-29 date: 2024-04-04 name: Portsmouth Hospitals NHS Trust class: OTHER_GOV briefSummary: This study aims to assess the concordance of international asthma guidelines in the diagnosis of asthma and explore the presence of airways disease using additional non-guideline physiologic criteria, such as IOS (impulse osciollometry), not included in the guidelines, but available in the Portsmouth lung function service. conditions: Asthma studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 750 type: ESTIMATED name: Lung function tests measure: International asthma guidelines scores measure: non-guideline physiologic criteria measure: non-guideline physiologic criteria for asthma. measure: Comparison of the diagnostic outcomes of each guideline with a "reference standard". sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Portsmouth Hospitals University NHS Trust status: RECRUITING city: Portsmouth country: United Kingdom name: Laura Marshall role: CONTACT phone: 02392286000 email: research.office@porthosp.nhs.uk lat: 50.79899 lon: -1.09125 hasResults: False
nctId: NCT06286072 id: YCEYHANS briefTitle: The Effect of Education and Reminder Messages on the Fatigue Level of Individuals With COPD overallStatus: RECRUITING date: 2023-11-01 date: 2024-01-30 date: 2024-03-30 date: 2024-02-29 date: 2024-02-29 name: Kirsehir Ahi Evran Universitesi class: OTHER briefSummary: COPD is an important respiratory system disease that progresses with damage to the airways.Increased mucus secretion and thickening in the airways causes obstruction.This obstruction causes symptoms such as shortness of breath, cough, phlegm and wheezing.The most obvious problem that the emerging symptoms will cause for the patient is fatigue.Coping with fatigue is an important problem in COPD.
* Fatigue level. The results obtained will be interpreted by comparing between 3 groups. conditions: Copd conditions: Fatigue studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomised Controlled Trial primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: PARTICIPANT count: 120 type: ESTIMATED name: Education and message measure: Fatigue Level measure: Dyspnea Severity measure: COPD general condition sex: ALL minimumAge: 18 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Yasemin CEYHAN status: RECRUITING city: Kırşehir state: Center zip: 40100 country: Turkey name: Yasemin CEYHAN, PhD role: CONTACT phone: +9054645898065 email: yasemin-ceyhan@hotmail.com role: CONTACT phoneExt: CEYHAN email: yasemin-ceyhan@hotmail.com name: Yasemin CEYHAN, PhD role: PRINCIPAL_INVESTIGATOR lat: 39.14583 lon: 34.16389 hasResults: False
nctId: NCT06286059 id: Phentolamine for CA-AKI briefTitle: Efficacy of Phentolamine in Prevention of Contrast-Associated Acute Kidney Injury After Complex PCI overallStatus: RECRUITING date: 2024-03-07 date: 2024-12-31 date: 2025-01-31 date: 2024-02-29 date: 2024-03-18 name: Helwan University class: OTHER briefSummary: To evaluate the efficacy and safety of phentolamine in prevention of CA-AKI following complex PCI in patients at high risk of CA-AKI. conditions: CA-AKI - Contrast-Associated Acute Kidney Injury conditions: Coronary Artery Disease conditions: Acute Coronary Syndrome conditions: Adrenergic Receptor Antagonist Adverse Reaction studyType: INTERVENTIONAL phases: PHASE2 phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomised controlled clinical trial primaryPurpose: PREVENTION masking: SINGLE maskingDescription: Single Blinded whoMasked: PARTICIPANT count: 60 type: ESTIMATED name: Phentolamine measure: Rate of CA-AKI measure: Peak of serum creatinine elevation measure: Duration of CA-AKI measure: Change in HR measure: Change in SBP measure: Change in DBP measure: Urine output measure: Rate of RRT measure: Rate of MACE measure: Rate of rehospitalization measure: Duration of hospitalization sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Badr university hospital status: RECRUITING city: Badr state: Cairo country: Egypt name: Mohammed Soliman, MBBCH role: CONTACT phone: +201032137563 email: Mohammed_Mostafa@med.helwan.edu.eg hasResults: False
nctId: NCT06286046 id: AG348-C-026 id: 2023-510289-28-00 type: OTHER domain: EU Clinical Trial Number briefTitle: A Study of Mitapivat in Participants With Sickle Cell Disease and Nephropathy overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2026-05 date: 2027-09 date: 2024-02-29 date: 2024-04-12 name: Agios Pharmaceuticals, Inc. class: INDUSTRY briefSummary: The primary purpose of this study is to evaluate the effect of mitapivat on albumin creatinine ratio (ACR) response in participants with sickle cell disease (SCD) and nephropathy. conditions: Sickle Cell Disease conditions: Nephropathy studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 40 type: ESTIMATED name: Mitapivat measure: Percentage of Participants With Albumin Creatinine Ratio (ACR) Response measure: Change From Baseline in Cystatin C and Creatinine-based Estimated Glomerular Filtration Rate (eGFRcr-cys) measure: Change From Baseline in Albumin Creatinine Ratio (ACR) measure: Percentage of Participants With Stable ACR measure: Annualized Rate of Emergency Room (ER) Visits measure: Annualized Rate of Days of Hospitalizations measure: Type, Frequency, Severity, and Relationship to Study Drug of Adverse Events (AEs) and Serious Adverse Events (SAEs) sex: ALL minimumAge: 16 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06286020 id: VR-Zhenqiu briefTitle: Effect of Virtual Reality Therapy on Dysphagia in Wallenberg Syndrome overallStatus: RECRUITING date: 2024-02-28 date: 2024-07 date: 2024-07 date: 2024-02-29 date: 2024-03-06 name: Zeng Changhao class: OTHER briefSummary: The goal of this clinical trial is to learn about on dysphagia in wallenberg syndrome. The main questions it aims to answer are:
Participants received conventional dysphagia treatment and Virtual Reality Therapy once a day for 14 days. Researchers compared the control group to see the effect and mechanism of Virtual Reality Therapy. conditions: Wallenberg Syndrome studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 80 type: ESTIMATED name: Virtual Reality Therapy name: Conventional dysphagia treatment measure: standardized swallowing assessment measure: Murray secretion scale measure: Rosenbek penetration-aspiration scale measure: swallowing-quality of life sex: ALL minimumAge: 18 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Xinzhu Rehabilitation Hospital status: RECRUITING city: Xinzhu country: Taiwan name: Haim Liu role: CONTACT lat: 22.46205 lon: 120.47335 hasResults: False
nctId: NCT06286007 id: PRIPASCO-2023 briefTitle: Prevalence and Impact of Pertussis and RSV on Asthma Severity and Control acronym: PRIPASCO overallStatus: RECRUITING date: 2023-12-21 date: 2024-07-31 date: 2026-07-01 date: 2024-02-29 date: 2024-03-01 name: Hospital Clinico Universitario de Santiago class: OTHER name: Translational Research In Airway Diseases Group (TRIAD) name: CIBER of Respiratory Diseases CIBERES name: Complexo Hospitalario Universitario de A Coruña name: Hospital de Galdakao name: Hospital Universitario Doctor Peset name: Hospital San Pedro de Alcantara name: Hospital Universitario Marqués de Valdecilla name: Hospital Universitario Vall d´Hebron name: Universitat Autonoma de Barcelona name: Universidade de Santiago de Compostela name: Consortium for Biomedical Research in Epidemiology and Public Health name: Hospital Universitario Virgen del Rocio name: Hospital de La Princesa name: University Hospital Virgen de las Nieves name: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau name: Germans Trias i Pujol Hospital name: Hospital Universitario de Navarra name: Hospital Universitario de Jerez de la Frontera name: Hospital El Bierzo name: Hospital Clinico Universitario San Cecilio name: Hospital Universitario Donostia name: Hospital Universitario Central de Asturias name: Hospital Universitario de la Ribera name: Hospital Costa del Sol name: Hospital General Universitario Dr. Balmis name: Hospital de Sagunto name: Hospital Lluis Alcanyís de Xàtiva name: Hospital Universitario Lucus Augusti name: Hospital del Mar name: Hospital Clínico Universitario Virgen de la Arrixaca name: Hospital Clinic of Barcelona briefSummary: The main objective is to estimate the annual symptomatic incidence of Bordetella pertussis and RSV infections in patients aged 18 years and over with asthma, which will be identified by PCR, for Bordetella pertussis and by PCR for RSV performed at a specific timepoint from onset of symptoms for each symptomatic Acute Respiratory Infection (ARI).
Participants will be asked to report to the investigator if they experience an asthma exacerbation or symptoms of acute respiratory infection with 2 years follow up conditions: Asthma conditions: Pertussis conditions: RSV Infection studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 784 type: ESTIMATED name: PCR measure: Incidence of Bordetella pertussis and RSV infections in adult patients with asthma, measure: To describe the seroprevalence of Bordetella pertussis in adult patients with asthma measure: To describe the seroprevalence of RSV in adult patients with asthma measure: To evaluate the severity and control of the asthma caused by either BP or RSV infection sex: ALL minimumAge: 18 Years maximumAge: 99 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hospital Clínico Universitario de Santiago de Compostela status: RECRUITING city: Santiago De Compostela state: A Coruña zip: 15706 country: Spain name: Francisco Javier González Barcala, Ph.D. role: CONTACT email: francisco.javier.gonzalez.barcala@sergas.es lat: 42.88052 lon: -8.54569 hasResults: False
nctId: NCT06285994 id: SRB2024016 briefTitle: Complications of High Frequency Jet Ventilation overallStatus: RECRUITING date: 2024-04-20 date: 2024-08-31 date: 2024-10-31 date: 2024-02-29 date: 2024-04-24 name: Erasme University Hospital class: OTHER briefSummary: High frequency jet ventilation (HFJV) has been introduced in 1967 as technique allowing ventilation with simultaneous access to the airway for bronchoscopy. Continuous improvement in the technique has led to a large use during interventional bronchoscopy, especially in large centers. However, complications occuring during the use of HFJV are poorly known. In this retrospective cohort study, the charts of all patients who had a bronchoscopy with the use of HFJV between 2019 and 2023 in our hospital will be analyzed. Primary outcome will the description of all complications during HFJV. Complications are defined as:
* DLCO (carbon monoxide diffusion) conditions: High-Frequency Jet Ventilation conditions: Bronchoscopy studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 1200 type: ESTIMATED name: High frequency jet ventilation measure: Occurence of complications measure: Prediction model of complications sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hôpital Universitaire de Bruxelles - Hôpital erasme status: RECRUITING city: Brussels zip: 1070 country: Belgium name: Denis Schmartz, MD role: CONTACT phone: +3225553919 email: denis.schmartz@hubruxelles.be lat: 50.85045 lon: 4.34878 hasResults: False
nctId: NCT06285981 id: OCI_2206 briefTitle: Retrospective Study Chimaera Long Nail in Adult Patient overallStatus: RECRUITING date: 2023-11-27 date: 2024-06-30 date: 2024-06-30 date: 2024-02-29 date: 2024-04-12 name: Orthofix s.r.l. class: INDUSTRY briefSummary: The CHIMERA study intends to evaluate the clinical benefits of the study medical device in the standard clinical practice. conditions: Pertrochanteric Fracture of Femur conditions: Intertrochanteric Fracture of Femur conditions: Subtrochanteric Fracture of Femur studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 44 type: ESTIMATED name: Chimaera Long Nail measure: percent of patients in wich bone union has been achieved measure: percent of patients that required a reoperation sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: AORN Sant'Anna e San Sebastiano status: NOT_YET_RECRUITING city: Caserta state: CE zip: 81100 country: Italy name: Gaetano Bruno role: CONTACT phone: 0823 232111 lat: 41.07262 lon: 14.33231 facility: Craeggi Hospital status: RECRUITING city: Florence state: FI zip: 50134 country: Italy name: Roberto Civinini role: CONTACT phone: 055 794 111 lat: 43.77925 lon: 11.24626 hasResults: False
nctId: NCT06285968 id: AAAU8937 id: P50MD017341 type: NIH link: https://reporter.nih.gov/quickSearch/P50MD017341 briefTitle: The DREAM Study: A Multidimensional Sleep Health Intervention for Reducing Cardiometabolic Health Inequities overallStatus: RECRUITING date: 2024-03-12 date: 2026-03-31 date: 2027-03-31 date: 2024-02-29 date: 2024-03-28 name: Columbia University class: OTHER name: National Institute on Minority Health and Health Disparities (NIMHD) briefSummary: The purpose of this randomized controlled trial is to evaluate the impact of a multidimensional sleep health promotion intervention on blood pressure, glycemic control indicators, anthropometric markers of adiposity, and lifestyle factors in Hispanic/Latina/o/x adults. Participants will be randomized into an intervention or a control group. The control arm will receive standard Life's Essential 8 cardiovascular health educational materials. The intervention arm will additionally receive a multi-component intervention aimed at improving sleep health based on evidence-based sleep hygiene education and established behavior change techniques that include personalized sleep health feedback, goal setting and establishing a sleep health plan, coaching, self-monitoring, and addressing light and noise in the sleep environment. Mixed methods will be used to understand implementation determinants, processes, and outcomes, ensuring the successful completion and future expansion of this intervention. conditions: Blood Pressure studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: NONE count: 250 type: ESTIMATED name: Multidimensional Sleep Health Promotion Intervention measure: Change in office systolic blood pressure measure: Change in office systolic blood pressure (sustained effect at 24 weeks) measure: Change in office diastolic blood pressure measure: Change in out-of-office blood pressure measure: Change in fasting glucose measure: Change in body weight measure: Change in waist circumference measure: Change in diet quality measure: Change in sleep health measure: Acceptability of Implementation measure: Feasibility of Implementation measure: Appropriateness of Implementation sex: ALL minimumAge: 30 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Columbia University Irving Medical Center, Mailman School of Public Health status: RECRUITING city: New York state: New York zip: 10032 country: United States name: Nour Makarem, PhD role: CONTACT email: nm2968@cumc.columbia.edu lat: 40.71427 lon: -74.00597 hasResults: False
nctId: NCT06285955 id: 307-reinforced teeth briefTitle: Clinical Trial of Metal-Reinforced Teeth Designed for Endoscopic Clips overallStatus: RECRUITING date: 2024-01-15 date: 2024-07-31 date: 2024-08-31 date: 2024-02-29 date: 2024-02-29 name: Beijing 302 Hospital class: OTHER briefSummary: Postoperative gastrointestinal complications following ESD, EMR, and EFTR procedures, such as gastrointestinal bleeding, diverticula, fistulas, perforations, and stent fixation, can be effectively treated through gradual endoscopic procedures. The technical limitations of traditional endoscopic hemoclips restrict their application. Although endoscopic suturing techniques are emerging, most are still in the exploratory phase. Therefore, the investigators have developed metal-reinforced teeth for hemoclips. This initial clinical study aims to validate the safety, feasibility, and effectiveness of reinforced teeth in clinical applications. The investigators also aim to explore the uses and limitations of this technology. The primary outcomes are the technical success rate and the clinical success rate. conditions: Pilot Study conditions: Clips studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 10 type: ESTIMATED measure: Clinical success rate measure: Technical success rate measure: Delayed bleeding rate measure: Delayed perforation rate sex: ALL minimumAge: 18 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The fifth Medical Center of Chinese PLA General Hospital status: RECRUITING city: Beijing state: Beijing zip: 100071 country: China name: Jindong Chu, MD role: CONTACT phone: +8615811201126 email: chu465292278@163.com name: Shuqian Hu role: CONTACT phone: +8618526504112 email: 1811045@mail.nankai.edu.cn name: Yan Liu, MD role: PRINCIPAL_INVESTIGATOR lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06285942 id: 277.535 id: CE366/2023 type: REGISTRY domain: CET AOU Maggiore della Carità di Novara briefTitle: EdOxaban in fRagIle Patients With Percutaneous Endoscopic GAstrostoMy and atrIal fIbrIllation acronym: ORIGAMI II overallStatus: RECRUITING date: 2024-02-01 date: 2025-01-31 date: 2025-01-31 date: 2024-02-29 date: 2024-02-29 name: Azienda Ospedaliero Universitaria Maggiore della Carita class: OTHER briefSummary: The goal of this interventional study is to describe the use of Edoxaban via PEG in patients with an indication to anticoagulation therapy. One arm will receive Edoxaban through PEG and the other arm will receive other Direct oral anticoagulants through PEG or subcutaneous heparin or LMWH.
Once enrolled, patients will be treated with a single daily dose of Edoxaban (60 or 30 mg according to specific indications). At day 4 after enrollment (steady state), evaluation of anti-FXa activity and thrombin generation assay will be performed on peripheral whole blood samples. At months 6 and 12 patients will be asked to complete the ACTS (Anti-Clot treatment scale) questionnaire specific for anticoagulation.
The main endpoint will be: the difference in the results of the Anti-Clot treatment scale questionnaire between the two groups evaluated at 12 months. conditions: Atrial Fibrillation conditions: Fragility studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE maskingDescription: An interim-analysis will be performed on the primary endpoint when at least 50% of patients will have been randomized and completed the 6 months follow-up. The interim-analysis will be performed by an independent statistician, blinded for the treatment allocation. The statistician will report to the independent data and safety monitoring board whoMasked: OUTCOMES_ASSESSOR count: 168 type: ESTIMATED name: Edoxaban name: No Edoxaban measure: Difference in Anti-Clot treatment scale (ACTS) questionnaire results among the two groups assessed at 6 and 12 months. measure: Number of cardio-embolic events at 6 and12 months measure: Number of bleeding events measure: Assessment of drugs efficacy by measuring the anti-factor Xa activity measure: Assessment of drugs efficacy by measuring the thrombin generation measure: Assess the quality of life measure: Cost-effectiveness analysis sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ospedale Policlinico San Martino status: RECRUITING city: Genova zip: 16132 country: Italy name: Pietro Ameri, Prof role: CONTACT phone: +39 010 3538975 email: pietro.ameri@unige.it lat: 44.40478 lon: 8.94438 facility: AOU Maggiore della Carità status: RECRUITING city: Novara zip: 28100 country: Italy name: Domenico D'Amario, Prof role: CONTACT phone: 0039 0321 3733141 email: domenico.damario@uniupo.it lat: 45.44694 lon: 8.62118 facility: Fondazione Policlinico Universitario Agostino Gemelli IRCCS status: RECRUITING city: Roma zip: 00168 country: Italy name: Cristiano Spada, Prof role: CONTACT phone: 06 30151 email: cristiano.spada@policlinicogemelli.it lat: 41.89193 lon: 12.51133 hasResults: False
nctId: NCT06285929 id: 2013209-1 briefTitle: ACS Community Access to Resources Education and Support acronym: ACS CARES overallStatus: ENROLLING_BY_INVITATION date: 2023-09-01 date: 2025-08-31 date: 2025-12-31 date: 2024-02-29 date: 2024-02-29 name: American Cancer Society, Inc. class: OTHER name: University of Alabama at Birmingham briefSummary: The goal of this study is to evaluate the pilot phase of ACS Cares to identify key implementation outcomes and assess effectiveness of the program to improve distress, enhance communication, and reduce missed appointments and healthcare utilization. conditions: Neoplasms studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 2000 type: ESTIMATED name: ACS CARES Student Navigation measure: Measure the impact of ACS CARES on patient-reported outcomes: SDOH barriers measure: Measure the impact of ACS CARES on patient-reported outcomes: Information Needs measure: Measure the impact of ACS CARES on patient-reported outcomes: Distress needs measure: Measure the impact of ACS CARES on patient-reported outcomes: Satisfaction with program measure: Measure the impact of ACS CARES on patient-reported outcomes: Unmet needs measure: Measure the impact of ACS CARES on patient-reported outcomes: Patient-provider communication measure: Measure the impact of ACS CARES on patient-reported outcomes: clinical trials knowledge measure: Measure the impact of ACS CARES on patient-reported outcomes: Patient activation measure: Measure the impact of ACS CARES on patient-reported outcomes: Financial toxicity measure: Measure the impact of ACS CARES on patient-reported outcomes: Quality of life measure: Context, Training, and Process Measures: Service Penetrance and Process Measures: Service Penetrance measure: Sociodemographic differences between ACS CARES supported and non-ACS CAREs supported patients measure: Impact of ACS CARES on treatment adherence and healthcare measure: Context, Training, and Process Measures: Volunteer Satisfaction sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: UCLA Health city: Los Angeles state: California zip: 90024 country: United States lat: 34.05223 lon: -118.24368 facility: American Cancer Society city: Kennesaw state: Georgia zip: 30144 country: United States lat: 34.02343 lon: -84.61549 facility: University of Iowa Health Care city: Iowa City state: Iowa zip: 52242 country: United States lat: 41.66113 lon: -91.53017 facility: Medical University Hospital Authority, Hollings Cancer Center city: Charleston state: South Carolina zip: 29492 country: United States lat: 32.77657 lon: -79.93092 hasResults: False
nctId: NCT06285916 id: NORA520-PT-US-1a briefTitle: A Study to Assess the Efficacy, Safety, and Tolerability of Oral NORA520 in Adults With Severe Postpartum Depression acronym: NuMom overallStatus: NOT_YET_RECRUITING date: 2024-02 date: 2026-02 date: 2026-03 date: 2024-02-29 date: 2024-02-29 name: Gerbera Therapeutics, Inc. class: INDUSTRY briefSummary: The purpose of this research study is to test the study drug, NORA520, as a possible treatment for severe postpartum depression (PPD). The trial aims to determine: